{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:29:16Z","timestamp":1788863356947,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,9]],"date-time":"2007-06-09T00:00:00Z","timestamp":1181347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2007,9,21]]},"DOI":"10.1007\/s12032-007-0028-6","type":"journal-article","created":{"date-parts":[[2007,6,8]],"date-time":"2007-06-08T15:04:55Z","timestamp":1181315095000},"page":"407-412","source":"Crossref","is-referenced-by-count":24,"title":["Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"M.","family":"Albertsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Friesland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Letocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Frykholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wagenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,9]]},"reference":[{"issue":"11","key":"28_CR1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/0360-3016(82)90447-3","volume":"8","author":"R Mantravadi","year":"1982","unstructured":"Mantravadi R, Lad T, Briele H, Liebner EJ. Carcinoma of the esophagus: sites of failure. Int J Radiat Oncol Biol Phys 1982;8(11):1897\u20131901.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"28_CR2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/1097-0142(19810715)48:2<329::AID-CNCR2820480219>3.0.CO;2-V","volume":"48","author":"AM Mandard","year":"1981","unstructured":"Mandard AM et al. Autopsy findings in 111 cases of esofhageal cancer. Cancer 1981;48:329\u201335.","journal-title":"Cancer"},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO;2-S","volume":"50","author":"L Anderson","year":"1982","unstructured":"Anderson L, Lad T. Autopsy findings in squamous cell carcinoma of the esophagus. Cancer 1982;50:1587\u201390.","journal-title":"Cancer"},{"issue":"3","key":"28_CR4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0022-5223(19)42966-8","volume":"55","author":"E Attah","year":"1968","unstructured":"Attah E, Hadju S. Benign and malignant tumors of the esophagus at autopsy. J Thoracic Cardiovasc surg 1968;55(3):396\u2013404.","journal-title":"J Thoracic Cardiovasc surg"},{"key":"28_CR5","first-page":"103","volume":"18","author":"A Bosch","year":"1979","unstructured":"Bosch A, Frias Z, Caldwell W, Jaeschke WH. Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol 1979;18:103\u201312.","journal-title":"Acta Radiol Oncol"},{"key":"28_CR6","unstructured":"Roth JA, Putman SB, Rich TA, Forastiere AA. In: De Vita V Jr. Hellman S, Rosenber S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997;980\u20131021."},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","volume":"33","author":"H Bleiberg","year":"1997","unstructured":"Bleiberg H, Conroy T, Paillot B et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216\u201320.","journal-title":"Eur J Cancer"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/oxfordjournals.annonc.a058098","volume":"3","author":"L Salts","year":"1992","unstructured":"Salts L, Kelson D. Combined modality therapy in the treatment of locoregional oesophageal cancer. Ann Oncol 1992;3:793\u20139.","journal-title":"Ann Oncol"},{"key":"28_CR9","first-page":"157","volume":"10","author":"T Iizuka","year":"1991","unstructured":"Iizuka T et al. Phase II study of CDDP\u00a0+\u00a05-FU for squamous esophageal carcinoma. JEOG cooperative study results. Proc Am Soc Clin Oncol 1991;10:157.","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2 Suppl 4","key":"28_CR10","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1053\/j.seminoncol.2005.04.005","volume":"32","author":"JR Rigas","year":"2005","unstructured":"Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol 2005;32(2 Suppl 4):S39\u201351.","journal-title":"Semin Oncol"},{"issue":"5","key":"28_CR11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1081\/CNV-200032951","volume":"22","author":"H Safran","year":"2004","unstructured":"Safran H et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22(5):670\u20137.","journal-title":"Cancer Invest"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1\u201310.","journal-title":"Control Clin Trials"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","volume":"86","author":"JA Ajani","year":"1994","unstructured":"Ajani JA et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Nat Cancer Inst 1994;86:1086\u201391.","journal-title":"J Nat Cancer Inst"},{"issue":"6","key":"28_CR14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/annonc\/mdh231","volume":"15","author":"K Muro","year":"2004","unstructured":"Muro K et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15(6):955\u20139.","journal-title":"Ann Oncol"},{"issue":"6","key":"28_CR15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1081\/CNV-120025092","volume":"21","author":"M Constantinou","year":"2003","unstructured":"Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancer. Cancer Invest 2003;21(6):887\u201396.","journal-title":"Cancer Invest"},{"issue":"4","key":"28_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/07357900600705268","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH et al. A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 2006;24(4):346\u201350.","journal-title":"Cancer Invest"},{"issue":"2","key":"28_CR17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.21986","volume":"107","author":"J Ajani","year":"2006","unstructured":"Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal and esophageal cancers. Cancer 2006;107(2):221\u201331.","journal-title":"Cancer"},{"issue":"12","key":"28_CR18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1007\/s10620-005-3038-2","volume":"50","author":"PC Enzinger","year":"2005","unstructured":"Enzinger PC et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50(12):2218\u201323.","journal-title":"Dig Dis Sci"},{"issue":"14 suppl 14","key":"28_CR19","first-page":"22","volume":"16","author":"DH Ilson","year":"2004","unstructured":"Ilson DH. Phase II trial of weekly irinotecan\/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;16(14 suppl 14):22\u20135.","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"28_CR20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/annonc\/mdh473","volume":"15","author":"C Pozzo","year":"2004","unstructured":"Pozzo C et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15(12):177\u201381.","journal-title":"Ann Oncol"},{"issue":"1","key":"28_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/MO:20:1:19","volume":"20","author":"M Airoldi","year":"2003","unstructured":"Airoldi M et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003;20(1):19\u201324.","journal-title":"Med Oncol"},{"key":"28_CR22","first-page":"91","volume":"4","author":"RE Wittes","year":"1985","unstructured":"Wittes RE, Adrianza ME, Parsons R et al. Compilation of phase II results with single antineoplastic agents. Cancer Treat Symp 1985;4:91\u2013130.","journal-title":"Cancer Treat Symp"},{"issue":"1","key":"28_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","volume":"13","author":"J Eskilsson","year":"1988","unstructured":"Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with Cisplatin and 5-fluorouracil. Radiother Oncol 1988;13(1):41\u20136.","journal-title":"Radiother Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-0028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-007-0028-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-0028-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T22:04:40Z","timestamp":1587593080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-007-0028-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,9,21]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s12032-007-0028-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,9]]}}}